Stock Track | Novo Nordisk Plummets 8.17% Intraday as Hims & Hers Launches Cheaper Wegovy Copycat Pill

Stock Track

02/06

Novo Nordisk A/S (NVO) shares plummeted 8.17% during intraday trading on Thursday, as the market reacted to heightened competitive pressure in the lucrative weight-loss drug market.

The sharp decline followed an announcement by telehealth company Hims & Hers Health that it will begin offering compounded copies of Novo Nordisk's Wegovy pill at an introductory price of $49 per month. This represents a significant discount compared to Novo's branded Wegovy, which costs $149 to $299 per month, raising concerns about market share erosion and pricing power for the Danish pharmaceutical giant.

Novo Nordisk responded to the announcement by condemning the move as "illegal mass compounding" that poses risks to patient safety, and stated it would pursue legal and regulatory action against Hims & Hers. The competitive threat was further underscored by BMO Capital Markets lowering its price target on Novo Nordisk shares from $57 to $45, maintaining a Market Perform rating.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1127858583"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1127858583\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1127858583?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-06 04:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1127858583","market":"nz","top_or_hot":-1,"title":"Stock Track | Novo Nordisk Plummets 8.17% Intraday as Hims & Hers Launches Cheaper Wegovy Copycat Pill","media":"Stock Track","content":"<p>Novo Nordisk A/S (NVO) shares plummeted 8.17% during intraday trading on Thursday, as the market reacted to heightened competitive pressure in the lucrative weight-loss drug market.</p><p>The sharp decline followed an announcement by telehealth company Hims & Hers Health that it will begin offering compounded copies of Novo Nordisk's Wegovy pill at an introductory price of $49 per month. This represents a significant discount compared to Novo's branded Wegovy, which costs $149 to $299 per month, raising concerns about market share erosion and pricing power for the Danish pharmaceutical giant.</p><p>Novo Nordisk responded to the announcement by condemning the move as \"illegal mass compounding\" that poses risks to patient safety, and stated it would pursue legal and regulatory action against Hims & Hers. The competitive threat was further underscored by BMO Capital Markets lowering its price target on Novo Nordisk shares from $57 to $45, maintaining a Market Perform rating.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Novo Nordisk Plummets 8.17% Intraday as Hims & Hers Launches Cheaper Wegovy Copycat Pill</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Novo Nordisk Plummets 8.17% Intraday as Hims & Hers Launches Cheaper Wegovy Copycat Pill\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-02-06 04:20</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Novo Nordisk A/S (NVO) shares plummeted 8.17% during intraday trading on Thursday, as the market reacted to heightened competitive pressure in the lucrative weight-loss drug market.</p><p>The sharp decline followed an announcement by telehealth company Hims & Hers Health that it will begin offering compounded copies of Novo Nordisk's Wegovy pill at an introductory price of $49 per month. This represents a significant discount compared to Novo's branded Wegovy, which costs $149 to $299 per month, raising concerns about market share erosion and pricing power for the Danish pharmaceutical giant.</p><p>Novo Nordisk responded to the announcement by condemning the move as \"illegal mass compounding\" that poses risks to patient safety, and stated it would pursue legal and regulatory action against Hims & Hers. The competitive threat was further underscored by BMO Capital Markets lowering its price target on Novo Nordisk shares from $57 to $45, maintaining a Market Perform rating.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"諾和諾德","start_time":0,"source_url":"","article_id":"1127858583","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1127858583","pubTimestamp":1770322814,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Novo Nordisk A/S (NVO) shares plummeted 8.17% during intraday trading on Thursday, as the market reacted to heightened competitive pressure in the lucrative weight-loss drug market.The sharp decline...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德"},"translate_title":"个股追踪|诺和诺德盘中暴跌8.17%，因Hims&Hers推出更便宜的Wegovy山寨药","themeId":"f0fce81d99e7c4115b5691df849cabad","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"Novo Nordisk A/S (NVO) shares plummeted 8.17% during intraday trading on Thursday, as the market reacted to heightened competitive pressure in the lucrative weight-loss drug market.The sharp decline followed an announcement by telehealth company Hims & Hers Health that it will begin offering compounded copies of Novo Nordisk's Wegovy pill at an introductory price of $49 per month. This represents a significant discount compared to Novo's branded Wegovy, which costs $149 to $299 per month, raising concerns about market share erosion and pricing power for the Danish pharmaceutical giant.Novo Nordisk responded to the announcement by condemning the move as \"illegal mass compounding\" that poses risks to patient safety, and stated it would pursue legal and regulatory action against Hims & Hers. The competitive threat was further underscored by BMO Capital Markets lowering its price target on Novo Nordisk shares from $57 to $45, maintaining a Market Perform rating.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}